fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Brolucizumab

All injection strengths: Limited Use (codes 620, 648)

Beovu · DIN 02496976 · 6 mg/0.05 mL · injection, 0.05 mL pre-filled syringe (preservative-free)

Limited Use, Reason for Use code 620, 648 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 620, 648 required
Write on scriptone applicable Reason for Use code, 620 or 648 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 620, 648
Reason for Use code 620 For the treatment of patients with mild-to-moderate neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye. Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified opthalmologist experienced in intravitreal injections. Patients receiving concurrent administration of verteporfin PDT (Visudyne), ranibizumab (Lucentis) or aflibercept (Eylea) are not eligible for reimbursement. Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 3 months. The interval between two doses should not be shorter than eight weeks. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy and should be discontinued if any of the following occurs: i. reduction in best corrected visual acuity (BCVA) in the treated eye to less than 15 letters (absolute) on two consecutive visits attributed to AMD in the absence of other pathology ii. reduction of BCVA of 30 letters or more compared to baseline and/or best recorded level since baseline as this may indicate either poor treatment effect or adverse event or both iii. evidence of deterioration of the lesion morphology despite treatment over three consecutive visits. For clarity, coverage will be provided for patients responding to therapy with Lucentis or Eylea who switch to Beovu. Coverage will NOT be provided for patients who have failed to respond to Lucentis or Eylea. Coverage limit: LU Authorization Period: 1 year Reason for Use code 648 For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 12 percent. Treatment should be initiated with an intravitreal injection every 6 weeks for the first 5 consecutive doses, followed by one injection every 8 to 12 weeks. An interval of 8 weeks may be considered for those with disease activity, whereas an interval of up to 12 weeks may be considered for those without disease activity. After the first 5 initiation doses, the interval between two doses should not be shorter than 8 weeks. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Beovu. Coverage will NOT be provided for patients who have failed to respond to another anti-VEGF agent. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Beovu · DIN 02496976 Manufacturer: Novartis Pharma Canada Inc.; listing date 2021-12-17 Health Canada: Marketed since 2020-05-15 · brand BEOVU · ATC S01LA06 BROLUCIZUMAB · form Solution · route Intravitreal · ingredients BROLUCIZUMAB 6 MG/0.05ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Beovu: Formulary list price $1390.00 per unit (the source does not state the unit; exact figure $1390.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496976)

Source record
DIN 02496976: Beovu Raw flags: sec12=Y, sec3=Y Item: 523600148; group id 619; item number 1586; lccId 00349; manufacturer id NOV Source form: Inj Sol-0.05mL Pref Syr (Preservative-Free); strength: 6mg/0.05mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1390.0000; ministry $1390.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496976 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98684
Shortage status: resolved shortage (ended June 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496976
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01LA): coverage varies; not interchangeable

  • Aflibercept (Aflivu): limited Use 694, 695, limited Use 729, 730, 731
  • Faricimab (Vabysmo): limited Use 649, 650, 725
  • Ranibizumab (Byooviz): limited Use 651, 652, 653, 654
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

AFLIBERCEPT

· 6 products · Limited Use, codes 729, 730, 731 (4), Limited Use, codes 694, 695 (2) · strengths: 2mg/0.05mL, 8mg/0.07mL · Inj Sol-0.05mL Pref Syr (Preservative-Free), Inj Sol-0.07mL Pref Syr, Inj Sol-0.07mL Vial Pk, Sol for Intravitreal Inj-0.05mL Vial Pk

FARICIMAB

· 2 products · Limited Use, codes 649, 650, 725 · strengths: 6mg/0.05mL · Inj Sol-0.05mL Pref Syr (Preservative-Free), Inj Sol-0.24mL Vial Pk (Preservative-Free)

RANIBIZUMAB

· 2 products · Limited Use, codes 651, 652, 653, 654 · strengths: 10mg/mL · Inj Sol-0.23mL Vial Pk (Preservative-Free)

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

DICLOFENAC SODIUM

· 6 products · General benefit · strengths: 0.1% · Oph Sol

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

SODIUM CROMOGLYCATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 2% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: diabetic macular edema, neovascular
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. AFLIBERCEPT · Limited Use, codes 729, 730, 731 (7), Limited Use, codes 694, 695 (2) • the treatment of neovascular (wet) age-related macular degeneration (AMD) PM: https://pdf.hres.ca/dpd_pm/00084821.PDF; date 2026-05-22; DIN 02535858; fetched 2026-09-10 Product monograph • the treatment of diabetic macular edema (DME) PM: https://pdf.hres.ca/dpd_pm/00084821.PDF; date 2026-05-22; DIN 02535858; fetched 2026-09-10 Product monograph RANIBIZUMAB · Limited Use, codes 651, 652, 653, 654 1 Indications MELVIZO (ranibizumab injection) is indicated for: • the treatment of neovascular (wet) age-related macular degeneration (AMD). PM: https://pdf.hres.ca/dpd_pm/00082902.PDF; date November 7, 2025; DIN 02525852; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS BEOVU® (brolucizumab injection) is indicated for: • The treatment of neovascular (wet) age-related macular degeneration (AMD). • The treatment of diabetic macular edema (DME). 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): No dosage regimen adjustment is required for geriatric use (see 4.2 Recommended Dose and Dosage Adjustment, Special Populations). https://pdf.hres.ca/dpd_pm/00077080.PDF PM date: Mar 12, 2020 Source product: BEOVU; DIN 02496976; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18